NO175131C - Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin - Google Patents

Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin

Info

Publication number
NO175131C
NO175131C NO891906A NO891906A NO175131C NO 175131 C NO175131 C NO 175131C NO 891906 A NO891906 A NO 891906A NO 891906 A NO891906 A NO 891906A NO 175131 C NO175131 C NO 175131C
Authority
NO
Norway
Prior art keywords
ranitidine
preparing
resin adsorbate
adsorbate
resin
Prior art date
Application number
NO891906A
Other languages
English (en)
Norwegian (no)
Other versions
NO891906L (no
NO175131B (no
NO891906D0 (no
Inventor
Stephen John Douglas
Fiona Ruth Bird
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888811167A external-priority patent/GB8811167D0/en
Priority claimed from GB888816185A external-priority patent/GB8816185D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO891906D0 publication Critical patent/NO891906D0/no
Publication of NO891906L publication Critical patent/NO891906L/no
Publication of NO175131B publication Critical patent/NO175131B/no
Publication of NO175131C publication Critical patent/NO175131C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
NO891906A 1988-05-11 1989-05-10 Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin NO175131C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888811167A GB8811167D0 (en) 1988-05-11 1988-05-11 Medicaments
GB888816185A GB8816185D0 (en) 1988-07-07 1988-07-07 Medicaments

Publications (4)

Publication Number Publication Date
NO891906D0 NO891906D0 (no) 1989-05-10
NO891906L NO891906L (no) 1989-11-13
NO175131B NO175131B (no) 1994-05-30
NO175131C true NO175131C (no) 1994-09-07

Family

ID=26293879

Family Applications (1)

Application Number Title Priority Date Filing Date
NO891906A NO175131C (no) 1988-05-11 1989-05-10 Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin

Country Status (35)

Country Link
US (1) US5032393A (pm)
JP (1) JP2944678B2 (pm)
KR (1) KR890016968A (pm)
CN (1) CN1027133C (pm)
AT (1) AT401614B (pm)
AU (1) AU624613B2 (pm)
BE (1) BE1002159A5 (pm)
CA (1) CA1337272C (pm)
CH (1) CH679011A5 (pm)
CY (1) CY1781A (pm)
DE (1) DE3915347C2 (pm)
DK (1) DK168934B1 (pm)
ES (1) ES2011573A6 (pm)
FI (1) FI92060C (pm)
FR (1) FR2631232B1 (pm)
GB (1) GB2218333B (pm)
GR (1) GR1000358B (pm)
HK (1) HK45094A (pm)
HU (2) HU204994B (pm)
IE (1) IE60722B1 (pm)
IL (1) IL90245A (pm)
IT (1) IT1232831B (pm)
LU (1) LU87515A1 (pm)
MX (1) MX173349B (pm)
MY (1) MY104013A (pm)
NL (1) NL8901188A (pm)
NO (1) NO175131C (pm)
NZ (1) NZ229064A (pm)
PH (1) PH27612A (pm)
PL (1) PL279377A1 (pm)
PT (1) PT90523B (pm)
RU (1) RU2033155C1 (pm)
SE (1) SE508343C2 (pm)
SG (1) SG48194G (pm)
YU (1) YU47674B (pm)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219563A (en) * 1988-05-11 1993-06-15 Glaxo Group Limited Drug adsorbates
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
SE9003902D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Solid dosage forms of a drug
GB8925484D0 (en) * 1989-11-10 1989-12-28 Glaxo Group Ltd Process
AU8546591A (en) * 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
SE9003903D0 (sv) * 1990-12-07 1990-12-07 Astra Ab New pharmaceutical formulations
EP0563294A1 (en) * 1990-12-21 1993-10-06 Richardson-Vicks, Inc. Polyamine drug-resin complexes
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP3207494B2 (ja) * 1992-04-02 2001-09-10 ロート製薬株式会社 水性懸濁製剤
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
GB9211148D0 (en) * 1992-05-26 1992-07-08 Smithkline Beecham Plc Novel treatment
GB9221414D0 (en) * 1992-10-13 1992-11-25 Glaxo Group Ltd Pharmaceutical compositions
MX9306393A (es) * 1992-10-16 1994-04-29 Glaxo Group Ltd Composiciones de ranitidina substancialmente libres de sabor amargo, proceso para su preparacion y composiciones farmaceuticas que las contienen.
US5665767A (en) * 1993-03-05 1997-09-09 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same
CA2121435C (en) * 1993-04-16 2002-01-22 Sheila M. Ratnaraj Aqueous pharmaceutical suspension and process for preparation thereof
GB9324409D0 (en) * 1993-11-27 1994-01-12 Smithkline Beecham Plc Novel composition
DK171127B1 (da) * 1994-04-22 1996-06-24 Gea Farmaceutisk Fabrik As Ranitidintablet med et hydroxypropylmethylcelluloseholdigt overtræk samt fremgangsmåde til at tilvejebringe dette overtræk
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
RU2131264C1 (ru) * 1996-06-04 1999-06-10 Московское производственное химико-фармацевтическое объединение им.Н.А.Семашко Противоязвенное средство в виде таблеток и способ его получения
US5980882A (en) * 1997-04-16 1999-11-09 Medeva Pharmaceuticals Manufacturing Drug-resin complexes stabilized by chelating agents
CA2305179A1 (en) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Oral administration preparation
AU733802B2 (en) * 1997-11-10 2001-05-24 Hisamitsu Pharmaceutical Co., Inc. Sustainedly releasing agents for medicines and sustainedly released medicinal compositions containing the same
JP4283355B2 (ja) * 1997-11-10 2009-06-24 久光製薬株式会社 薬剤用徐放化剤及びそれを含有した徐放性医薬組成物
RU2154469C2 (ru) * 1998-08-10 2000-08-20 Открытое акционерное общество фармацевтическая фирма "ЗДОРОВЬЕ" Способ получения таблеток ранитидина
RU2203048C2 (ru) * 1998-08-18 2003-04-27 Леонидов Николай Борисович Физически устойчивая рентгеноаморфная форма ранитидина гидрохлорида с повышенной противоязвенной активностью и способ ее получения
NZ516536A (en) * 1999-07-14 2003-09-26 Schering Plough Ltd Taste masking or oral quinolone liquid preparations using ion exchange resins
US6514492B1 (en) 1999-07-14 2003-02-04 Schering-Plough Veterinary Corporation Taste masking of oral quinolone liquid preparations using ion exchange resins
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US7067116B1 (en) * 2000-03-23 2006-06-27 Warner-Lambert Company Llc Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1
US20020031490A1 (en) * 2000-07-27 2002-03-14 Bellamy Simon Andrew Method for preparing resinates
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
JP4268052B2 (ja) * 2002-01-18 2009-05-27 ローム アンド ハース カンパニー レジネートの調製方法
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
WO2007001300A1 (en) * 2005-06-28 2007-01-04 Ucb, S.A. Multiple active drug-resin conjugate
US20050142097A1 (en) * 2003-12-29 2005-06-30 Deepak Thassu Multiple active drug resin conjugate
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
CA2618187C (en) * 2005-09-21 2011-06-21 Chong Kun Dang Pharmaceutical Corp. Novel resinate complex of s-clopidogrel and production method thereof
DK2428205T3 (da) 2006-03-16 2012-10-22 Tris Pharma Inc Modificerede formuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
CN100411626C (zh) * 2006-08-28 2008-08-20 浙江大学 缓释型碘补充剂的制备方法
WO2008042218A1 (en) * 2006-10-03 2008-04-10 Tris Pharma, Inc. Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
CN100450548C (zh) * 2006-12-22 2009-01-14 江苏奥赛康药业有限公司 一种波拉克林树脂组合物的口腔贴片及其制备方法
CN107048483A (zh) * 2007-10-11 2017-08-18 菲利普莫里斯生产公司 无烟烟草产品
TW200938186A (en) * 2008-02-13 2009-09-16 Eurand Inc Orally disintegrating tablet compositions of ranitidine and methods of manufacture
JP5560701B2 (ja) * 2008-12-26 2014-07-30 ライオン株式会社 ラニチジン含有医薬固形製剤及びラニチジン担持粒子の製造方法
JP5412966B2 (ja) * 2009-06-08 2014-02-12 ライオン株式会社 粒状製剤
US8357398B2 (en) * 2009-10-21 2013-01-22 Alitair Pharmaceuticals Inc. Benzonatate compositions and methods of use
CN102198118B (zh) * 2011-03-28 2012-08-29 于晓勇 一种治疗呕吐的口腔药物制剂及其制备方法
CN102138915A (zh) * 2011-03-28 2011-08-03 于晓勇 一种口服药物制剂及其制备方法
EP2884961B1 (en) 2012-08-15 2019-03-06 Tris Pharma Inc. Methylphenidate extended release chewable tablet
RU2761346C2 (ru) * 2016-11-01 2021-12-07 Джонсон энд Джонсон Консьюмер Инк. Жидкая пероральная фармацевтическая лекарственная форма, содержащая антагонист h2-рецептора гистамина и антацид
CN112020350A (zh) 2018-04-27 2020-12-01 强生消费者公司 液体口服药物剂型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR803638A (fr) * 1935-06-21 1936-10-05 Système de freinage pour portes coulissantes
US2828207A (en) * 1955-11-14 1958-03-25 Du Pont Fortification of feed
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
US2970053A (en) * 1958-10-28 1961-01-31 Pfizer & Co C Oleandomycin resin adsorbate
US3138525A (en) * 1961-06-16 1964-06-23 Hoffmann La Roche Castor wax-amprotropine-resin compositions
US3949068A (en) * 1964-02-20 1976-04-06 University Of Alabama In Birmingham Medical And Educational Foundation Pharmaceutical compositions
GB1180233A (en) * 1966-02-23 1970-02-04 Jean Astruc Modified Spiramycin
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
GB1218102A (en) * 1968-03-15 1971-01-06 Philips Nv Improvements in medicaments comprising drug/ion-exchange resin compounds
JPS5146154B2 (pm) * 1972-05-11 1976-12-07
GB1462356A (en) * 1973-07-10 1977-01-26 Beecham Group Ltd Pharmaceutical compositions
JPS51125708A (en) * 1974-07-23 1976-11-02 Beecham Group Ltd Production of betaalactam antibiotic complex
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
CY1306A (en) * 1980-10-01 1985-12-06 Glaxo Group Ltd Aminoalkyl furan derivative
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
EP0077529B1 (de) * 1981-10-16 1985-07-17 Sanol Schwarz GmbH Arzneimittelformulierung
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
JPS6369038A (ja) * 1986-09-10 1988-03-29 Canon Inc 光カ−ド記録媒体
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents

Also Published As

Publication number Publication date
SE8901671L (sv) 1989-11-12
CA1337272C (en) 1995-10-10
IL90245A (en) 1994-04-12
JPH02111719A (ja) 1990-04-24
CY1781A (en) 1995-10-20
BE1002159A5 (fr) 1990-08-14
NO891906L (no) 1989-11-13
IT8947938A0 (it) 1989-05-10
IE891527L (en) 1989-11-11
HUT50036A (en) 1989-12-28
YU97189A (en) 1990-06-30
RU2033155C1 (ru) 1995-04-20
GR890100314A (en) 1990-03-12
CN1027133C (zh) 1994-12-28
AU624613B2 (en) 1992-06-18
NO175131B (no) 1994-05-30
CN1037651A (zh) 1989-12-06
FR2631232B1 (fr) 1993-11-19
GB8910706D0 (en) 1989-06-28
NZ229064A (en) 1991-12-23
DE3915347C2 (de) 1994-11-03
GR1000358B (el) 1992-06-30
FI92060C (fi) 1994-09-26
GB2218333B (en) 1991-11-06
ES2011573A6 (es) 1990-01-16
SG48194G (en) 1994-11-25
YU47674B (sh) 1996-01-08
SE508343C2 (sv) 1998-09-28
FI892248L (fi) 1989-11-12
FI892248A0 (fi) 1989-05-10
HU204994B (en) 1992-03-30
SE8901671D0 (sv) 1989-05-10
DK229489A (da) 1989-11-12
FI92060B (fi) 1994-06-15
IE60722B1 (en) 1994-08-10
LU87515A1 (fr) 1990-06-12
MY104013A (en) 1993-10-30
IT1232831B (it) 1992-03-05
PH27612A (en) 1993-08-31
HU211592A9 (en) 1995-12-28
DK168934B1 (da) 1994-07-11
FR2631232A1 (fr) 1989-11-17
HK45094A (en) 1994-05-13
GB2218333A (en) 1989-11-15
AU3461789A (en) 1989-11-16
JP2944678B2 (ja) 1999-09-06
KR890016968A (ko) 1989-12-14
PT90523B (pt) 1994-10-31
MX15983A (es) 1993-10-01
CH679011A5 (pm) 1991-12-13
ATA112089A (de) 1996-03-15
NO891906D0 (no) 1989-05-10
PT90523A (pt) 1989-11-30
DE3915347A1 (de) 1989-11-16
MX173349B (es) 1994-01-22
DK229489D0 (da) 1989-05-10
AT401614B (de) 1996-10-25
US5032393A (en) 1991-07-16
NL8901188A (nl) 1989-12-01
PL279377A1 (en) 1990-01-22
IL90245A0 (en) 1989-12-15

Similar Documents

Publication Publication Date Title
NO175131C (no) Fremgangsmåte for fremstilling av et harpiksadsorbat av ranitidin
NO178321C (no) Fremgangsmåte for fremstilling av et næringsmiddelmateriale
NO176695C (no) Fremgangsmåte for fremstilling av et smaksmaskert preparat av cefuroksim aksetil
PT91631A (pt) A process for the preparation of cyclic graf-analogs ii
NO880520D0 (no) Fremgangsmaate for fremstilling av et cholestyraminpreparat
FI890283A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 25-hydroksi-vitamiinin D-johdannaisten valmistamiseksi
FI884910A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten bentsopyraanijohdannaisten valmistamiseksi
FI93106C (fi) Menetelmä lääkeaineina käyttökelpoisten 2-iminobentsotiatsoliinijohdannaisten valmistamiseksi
FI891677L (fi) Menetelmä 4-demetoksidaunomysinonin valmistamiseksi
NO171792C (no) Fremgangsmaate for fremstilling av en friradikal-addisjonspolymer
FI895983A0 (fi) Menetelmä lääkeaineina käyttökelpoisten 2-bentsotiatsoliinijohdannaisten valmistamiseksi
FI890186A7 (fi) Menetelmä 1-hydroksialkyyli-5-nitroimidatsolien valmistamiseksi
NO171910C (no) Fremgangsmaate for fremstilling av 1-alkyl-5-nitroimidazoler
BR8902634A (pt) Metodo de preparacao de uma polpa
NO942153D0 (no) Fremgangsmåte for fremstilling av et baryttkjelestensinhiberende preparat
PT86938A (pt) Process for the preparation of a macrocyclic compound
NO176915C (no) Fremgangsmåte for fremstilling av et hirudin-derivat
FI92188C (fi) Menetelmä terapeuttisesti käyttökelpoisten fenoksialkyylipyrokatekolijohdannaisten valmistamiseksi
ZA881513B (en) Process for the preparation of a modified epoxy resin
FI890188A7 (fi) Menetelmä 1-hydroksialkyyli-2-metyyli-5-nitroimidatsolien valmistamiseksi
FI890717A7 (fi) Menetelmä (R)-glysidyyliestereiden valmistamiseksi
FI91069B (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi
FI95989C (fi) Menetelmä letkuravinnon valmistamiseksi
GB2217713B (en) Process for the preparation of a furan derivative
NO174745C (no) Fremgangsmåte for fremstilling av cycloalkadiener